Google
NVS 株価分析 — NOVARTIS AG ADR (Healthcare >> Drug Manufacturers - General)
NVS に関するよくある質問
NVSのPER（株価収益率）は？
NOVARTIS AG ADR（NVS）は現在PER 23.60倍で取引されています。
NVSのROE（自己資本利益率）は？
NOVARTIS AG ADRのROEは30.71%です。
NVSの配当利回りは？
NOVARTIS AG ADRの配当利回りは2.99%です。
NVSの品質スコア（Quality Score）は？
当社のAIはNVSの総合財務品質を100点中92点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
NVSは今が買い時ですか？
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
NVSはどのセクターに属しますか？
NOVARTIS AG ADRはHealthcare >> Drug Manufacturers - Generalセクターに分類されます（NYSE市場）
NVS AI Analysis Summary
Our AI summary for NVS: NOVARTIS AG ADR (NYSE), Healthcare >> Drug Manufacturers - General sector. The stock currently trades at a P/E of 23.60, ROE of 30.71%, a dividend yield of 2.99%. Its financial Quality Score stands at 92/100 — fundamentals stronger than most of the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 156.15
Price
-2.29
(-1.45%)
Day Change
|
|
|---|
NVS, ファンダメンタルスコアはexcellent ( ファンダメンタル = 92) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Good
- Reason
-
ROAがROEに比べて低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | N/A |
| Magic Formula Rank by ROA |
925
|
| Magic Formula Rank by ROE |
925
|
| Magic Formula Rank by ROIC |
1225
|
| Price | 156.15 |
| PBV / Sector |
7.18 / 2.68
|
| Earning Per Share | 6.62 |
| PE / Sector |
23.60 / 27.65
|
| PEG or PE/Growth / Sector |
0.55 / 0.28
GOOD
|
| Average 1M Daily Value |
264.00 M
GREAT
|
| Average 1W Daily Value |
256.89 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
56% |
| ポイントになる統計 |
|
77% |
| 配当 |
|
12% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:15 |
| Symbol | NVS |
| Name | NOVARTIS AG ADR |
| Sector | Healthcare >> Drug Manufacturers - General |
| Market | NYSE |
| Listed Shares | 1,900.71 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 301,149.26 / 256,404.20 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Lichtstrasse 35, Basel, Switzerland, 4056
Phone: 41 61 324 11 11
Website: https://www.novartis.com
Employees: 75,267
Description: Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - General
Click a bubble to view stock details · Bubble size represents market capitalization share
